(Andersen et al - Altreos



PUBLISHED Journal Articles

Abuse Liability and Addiction Research

Setnik B, Goli V, Levy-Cooperman N, Mills C, Shram M, Smith I. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag. 2013 Jul-Aug;18(4):e55-62.

Zou S, Funk D, Shram MJ, Lê AD. Effects of stressors on the reinforcing efficacy of nicotine in adolescent and adult rats. Psychophamacol, 2013 epub ahead of print.

Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):13-23.

Schoedel KA, Rolleri, RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E. Assessing subjective and physiological effects following intranasal administration of a new formulation of immediate release oxycodone HCI (OxectaTM) tablets in nondependent recreational opioid users. J Opioid Manag 2012 Sep-Oct:8(5):315-27.

Li S, Zou S, Coen K, Funk D, Shram MJ, Lê AD. Sex differences in yohimbine-induced increases in the reinforcing efficacy of nicotine in adolescent rats. Addict Biol. 2012 Jul 11. doi: 10.1111/j.1369-1600.2012.00473.x.

Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: A randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Clin Psychopharmacol. 2012 Aug;32(4):492-502.

Schoedel KA, Chen N, Hillard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011 Jun 13. doi: 10.1002/hup.1196.

Schoedel KA, McMorn S, Zerbe K, Chakraborty B, Potts SL, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone. J Opioid Manag. 2011;7(3):179-92.

Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT(2C)) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011 May;89(5):683-92.

Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. Drug Alcohol Depend. 2011 Apr 1;114(2-3):185-93.

Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010 Jul;88(1):69-78.

Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. Drug Alcohol Depend. 2010 Dec 1;112(3):173-7.

Shram MJ, Sathyan G, Khanna S, Tudor IC, Nath R, Thipphawong J, Sellers EM. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010; 30(1): 25-33.

Shram MJ, Lê AD. Adolescent male Wistar rats are more responsive than adult rats to the conditioned rewarding effects of intravenously administered nicotine in the place conditioning procedure. Behav Brain Res. 2010 Jan 20;206(2):240-4.

Schoedel KA; Sellers EM: Assessing abuse liability during drug development: Changing standards and expectation. Clin Pharmacol Ther 2008; 83(4): 622-626.

Shram MJ, Siu EC, Li Z, Tyndale RF, Lê AD. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl). 2008 Jun;198(2):181-90.

Shram MJ, Funk D, Li Z, Lê AD. Nicotine self-administration, extinction responding and reinstatement in adolescent and adult male rats: evidence against a biological vulnerability to nicotine addiction during adolescence. Neuropsychopharmacology. 2008 Mar;33(4):739-48.

Shram MJ, Li Z, Lê AD. Age differences in the spontaneous acquisition of nicotine self-administration in male Wistar and Long-Evans rats. Psychopharmacology (Berl). 2008 Mar;197(1):45-58.

Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007; 47(12): 1476-1488.

Parasrampuria DA, Schoedel K, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate: A placebo-controlled, randomized, double blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007; 27(5): 459-467.

Shram MJ, Funk D, Li Z, Lê AD. Acute nicotine enhances c-fos mRNA expression differentially in reward-related substrates of adolescent and adult rat brain. Neurosci Lett. 2007 May 18;418(3):286-91.

Wall TL, Schoedel KA, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine Tob Res. 2007 Sep;9 Suppl 3:S459-74. Review.

Shram MJ, Funk D, Li Z, Lê AD. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine.

Psychopharmacology (Berl). 2006 Jun;186(2):201-8.

Lê AD, Li Z, Funk D, Shram M, Li TK, Shaham Y. Increased vulnerability to nicotine self-administration and relapse in alcohol-naive offspring of rats selectively bred for high alcohol intake. J Neurosci. 2006 Feb 8;26(6):1872-9.

Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004 Sep;14(9):615-26.

Shram MJ, Bahroos M, Beleskey JI, Tampakeras M, Lê AD, Tomkins DM. Motor impairing effects of ethanol and diazepam in rats selectively bred for high and low ethanol consumption in a limited-access paradigm. Alcohol Clin Exp Res. 2004 Dec;28(12):1814-21.

Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim Biophys Acta. 2003 Feb 17;1619(3):283-90. Review.

Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacology 2003; 63: 96-104 (CSCP 2003 publication award recipient).

Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol 2001; 62: 1025-1036.

Clinical Pharmacology, Neuropharmacology and CNS Drug Development

Schoedel KA, Geoffroy P. CNS drug liabilities in early phase clinical trials, May 2013.

Schoedel KA, Harrison SJ. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Curr Pharm Des. 2012;18(32):5008-14. Review.

Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012 Jun 19. doi: 10.2165/11633850-000000000-00000.

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: Examination of current bioequivalence criteria. Clin Ther. 2012 Apr 16.

Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clin Drug Investig. 2012 Jan 25. doi: 10.2165/11599870-000000000-00000.

Nadkarni NK, Levy-Cooperman N, Black SE. Functional correlates of instrumental activities of daily living in mild Alzheimer's disease. Neurobiol Aging. 2012 Jan;33(1):53-60.

McMorn S, Schoedel KA, Sellers EM. Effects of low-dose opioids on cognitive dysfunction. J Clin Oncol. 2011 Nov 10;29(32):4342-3.

Ramirez J, Gibson E, Quddus A, Lobaugh NJ, Feinstein A, Levine B, Scott CJ, Levy-Cooperman N, Gao FQ, Black SE. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage. 2011 Jan 15;54(2):963-73.

Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. Pain Physician. 2010 Dec;13(6):561-73.

Levy-Cooperman N, Burhan AM, Rafi-Tari S, Kusano M, Ramirez J, Caldwell C, Black SE.

Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J Psychiatry Neurosci. 2008 May;33(3):218-26.

Levy-Cooperman N, Ramirez J, Lobaugh NJ, Black SE. Misclassified tissue volumes in Alzheimer disease patients with white matter hyperintensities: importance of lesion segmentation procedures for volumetric analysis.

Stroke. 2008 Apr;39(4):1134-41.

Levy-Cooperman N, Lobaugh NJ, Caldwell C, Gao F, Black SE. Subcortical hyperintensities in Alzheimer's disease: no clear relationship with executive function and frontal perfusion on SPECT. Dement Geriatr Cogn Disord. 2007;24(5):380-8.

Hampson E, Finestone JM, Levy N.  Menstrual cycle effects on perceptual closure mediate changes in performance on a fragmented objects test of implicit memory.  Brain and Cognition 2005;57(2):107-10.

Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel KA, Tyndale RF, Benowitz NL.

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004 Jul;76(1):64-72.

Publications In Press

Harris SC, Perrino PJ, Sellers EM, Smith I, Shram M, Bartlett C, Colucci SV. Abuse potential, pharmacokinetics, pharmacodynamics and safety of intranasally administered crushed oxycodone HCl tamper-resistant controlled-release in recreational opioid users. In press at J Clin Pharmacology.

Book chapters

__________________________________________________________________________

Little HJ, McKinzie DL, Setnik B, Shram MJ, Sellers EM. Pharmacotherapy of dependence: Improving translation from the bench to the clinic, Chapter 5. In: Animal and Translational Models for CNS Drug Discovery, Volume 3: Reward Deficit Disorders. McArthur R, Borsini F (eds.), Academic Press, Burlington, MA, 2008. pp. 91 – 106

Romach MK, Schoedel KA, Sellers EM. Drugs used for anxiety, stress disorders, and insomnia in principles of medical pharmacology, 7th Edition (2007), Kalant, H., Grant, D.M. and J. Mitchell (eds.). Elsevier Canada, Toronto.

Sellers EM, Schoedel KA, Romach MK. Drug interactions. Principles of Medical Pharmacology, 7th Edition (2007), Kalant, H., Grant, D.M. and J. Mitchell (eds.). Elsevier Canada, Toronto.

Conferences/abstracts (Presented or Accepted; FROM 2005)

___________________________________________________________________________

Abuse Liability and Addiction Research

Levy-Cooperman N, McIntyre G, Bonifacio L, Davenport M, Covingto P, Dove S,

Almenoff J, Chakraborty B, Schoedel K, McDonnell M, Sellers EM. Lack of subjective abuse-related effects of intranasal eluxadoline: a novel mu-delta opiate modulator for oral use in IBS-d. Accepted for the American College of Neuropsychopharmacology Meeting, December 8-12, 2013, Hollywood, FL.

Levy-Cooperman N, Chakraborty B, Hopyan T, Cheng H, Blum D, Schoedel KA. Abuse potential assessment of eslicarbazepine acetate in healthy male and female recreational sedative users. Accepted for the American Epilepsy Society meeting, December 6-10, 2013, Washington, DC.

Schoedel KA. Interpretation of Human Abuse Potential Studies and Clinically Important Responses to ADFs. Abuse-Deterrent Formulation Science Meeting, Sep 30-Oct1, 2013, Bethesda, MD. [Invited oral presentation]

Schoedel KA. Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3). Abuse-Deterrent Formulation Science Meeting, Sep 30-Oct1, 2013, Bethesda, MD. [Invited oral presentation]

Shram MJ. PK/PD Analysis in the Assessment of Abuse Deterrence. Abuse-Deterrent Formulation Science Meeting, Sep 30-Oct1, 2013, Bethesda, MD. [Invited oral presentation]

Levy-Cooperman N. Structuring the Submission of Abuse Deterrence Data and Formulating the ADF Label. ADF Science Meeting, Sep 30-Oct1, 2013, Bethesda, MD. [Invited oral presentation]

Wang Y, Perrino P, Schoedel KA, Geoffroy P, Colucci SV, Harris SC. Abuse Potential of Chewed or Intact Oxycodone/Naloxone (OXN) Tablets in Methadone-Stabilized, Opioid-Dependent Subjects when Administered Orally. Pain Week, 2013, Las Vegas, NV.

Harris SC, Perrino PJ, Shram M, Bartlett CB, Colucci SV, Wang Y. Abuse Potential of Oxycodone/Naloxone (OXN) Tablets Administered Intranasally in Non-Dependent Recreational Drug Users with Moderate Opioid Experience. Pain Week, 2013, Las Vegas, NV.

Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC. Abuse Potential of Oxycodone/Naloxone Solution Administered Intravenously in Non-Dependent Recreational Drug Users with Moderate Opioid Experience. Pain Week, 2013, Las Vegas, NV.

Perrino PJ, Colucci CV, Shram M, Bartlett C, Sellers EM, Wang Y, Harris SC. Relative Attractiveness of Oxycodone/Naloxone (OXN): Comparative Assessment of Tampering Potential and Recreational Drug User Preferences for Different Opioid Formulations. Pain Week, 2013, Las Vegas, NV.

Levy-Cooperman N, Mills C, Shram MJ, Schoedel KA. Reducing Subject Burden: Identifying Critical Measures in Human Abuse Potential Studies using Factor Analysis. College on Problems of Drug Dependence, June 16-20, 2013, San Diego, CA.

Levy-Cooperman, N. Clinical assessment of abuse deterrent formulations. College on Problems of Drug Dependence, June 16-20, 2013, San Diego, CA. [Invited oral presentation]

Schoedel KA, Sokolowska M. Assessment of abuse deterrent and tamper resistant technologies part II: New directions. Workshop at College on Problems of Drug Dependence, June 16-20, 2013, San Diego, CA. [Workshop Chair]

Levy-Cooperman N, Mills C, Shram MJ, Schoedel KA. Reducing subject burden: Identifying critical measures in human abuse potential studies using factor analysis. College on Problems of Drug Dependence, June 16-20, 2013, San Diego, CA.

Schoedel KA, Setnik B, Roland C, Pixton G, Shram MJ, Levy-Cooperman N. Review of human abuse potential study methodology for abuse-deterrent formulations (ADFs). College on Problems of Drug Dependence, June 16-20, 2013, San Diego, CA.

Levy-Cooperman N, Schoedel KA. Opioid-related adverse events in clinical trials – Indicators for abuse liability. American Pain Society 32nd Annual Scientific Meeting, May 8-11, 2013, New Orleans, LA.

Turncliff RZ, Silverman B, Du Y, Vince B, Sellers EM, Chen N, Shram M, Todtenkopf MS, Ehrich E. ALKS 5461, a Novel Opioid Receptor Modulator, Reduces the Subjective Effects of Cocaine and was Safe and Well Tolerated during Concurrent Cocaine Administration. 51st Annual Meeting of the American College of Neuropsychopharmacology, December 2-6, 2012, Hollywood, FL.

Schoedel KA, Sokolowska M. Assessment of abuse deterrent and tamper resistant technologies: from the bench-top to the users. Workshop at College on Problems of Drug Dependence, June 9-14, 2012, Palm Springs, CA. [Workshop Chair]

Shram MJ. A focus on the clinical assessment of abuse-deterrent formulations. College on Problems of Drug Dependence, June 9-14, 2012, Palm Springs, CA. [Invited oral presentation]

Shram MJ, Levy-Cooperman N, Chen N, Mills C, Bartlett C, Setnik B, van der Graaf P, Ratcliffe S, Schoedel KA. Sensitivity and performance of derived parameters from human abuse potential studies. College on Problems of Drug Dependence, June 9-14, 2012, Palm Springs, CA.

Schoedel KA, Shram M, Levy-Cooperman N, Chen N, Mills C, Bartlett C, Setnik B, van der Graaf P, Ratcliffe S. Defining clinically important differences in subjective abuse potential measures. College on Problems of Drug Dependence, June 9-14, 2012, Palm Springs, CA.

Setnik B, Goli V, Levy-Cooperman N, Smith I. Self reports of prescription opioid misuse, abuse and diversion in a sample of recreational opioid users. Canadian Pain Society Annual Conference, May 23-26, 2012, Whistler, BC.

Setnik B, Goli V, Levy-Cooperman N, Smith I. Assessing the Abuse Potential of Crushed EMBEDA® Compared to Crushed Morphine Sulfate Controlled Release Tablets and Placebo in Non-Dependent, Recreational Opioid Users Following Intranasal Administration. Canadian Pain Society Annual Conference, May 23-26, 2012, Whistler, BC.

Schoedel KA. Human Subject abuse potential studies: validated scales and statistical and clinical assessments. Science of Abuse Liability Assessment, a Joint NIDA-FDA Public Workshop, November 10, 2011, Rockville, MD. [FDA invited oral presentation]

Rolleri RL, Faulknor J, Schoedel KA, Pixton GC, Chen N, Bass A, Sellers EM. Intranasal abuse potential of an IR oxycodone formulation. American Academy of Pain Management 22nd Annual Clinical Meeting, September 20-23, 2011, Las Vegas, NV.

Setnik B, Cleveland JM, Goli V, Levy-Cooperman N, Smith I. Assessing the abuse potential of crushed EMBEDA® compared to crushed morphine sulfate controlled-release tablets and placebo in non-dependent, recreational opioid users following intranasal administration. PAINWeek® 2011; September 7–10, 2011; Las Vegas, NV.

Romach MK, Levy-Cooperman N, Sellers EM, Schoedel KA. Can clinical trial adverse events predict pharmacological response? College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL.

Schoedel KA, Frey J, Chakraborty B, Myroslava MK, Sellers EM. Receptor sub-type selectivity affects subjective and cognitive effects of GABA modulators in humans: A comparison of lorazepam and a novel GABAAα2/GABAAα3 selective modulator. College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL [selected as an oral presentation].

Sellers EM, Romach MK, Schoedel KA. Update on formulations to deter tampering. College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL.

Shram MJ, Schoedel KA, Chakraborty B, Setnik B, Goli V, Romach MK. The relationship between objective and subjective effects measures used in abuse liability testing: An exploratory analysis using opioid agonists. College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL.

Schoedel KA. When clinical adverse events signal drug abuse potential. Session co-chair at College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL.

Rolleri R, Faulknor J, Schoedel KA, Pixton G, Chen N, Bass A, Sellers EM. Intranasal Abuse Potential of Immediate-Release Oxycodone (Acurox®; IROA) Formulated to Deter Abuse. College on Problems of Drug Dependence, June 21-25, 2011, Hollywood, FL.

Blanchard R, Sun H, McCrea J, Schoedel KA, Ngo P, Li X, Panebianco D, Rosen L, Sellers EM, Ho T, Murphy G. The CGRP receptor antagonist telcagepant does not demonstrate potential for recreational abuse: results from a clinical study. 63rd American Academy of Neurology Annual Meeting, April 2011, Honolulu, Hawaii.

Schoedel KA, Cronenberger C, Corrigan C, Fullerton T, Fang J, Martin N, Ryan N, Lopez R, Mordenti J, Smith I, Sellers EM. Drug abuse potential of dimebon: A randomized, double-blind, single-dose placebo- and active-controlled crossover study in healthy recreational polydrug users. American Society of Clinical Pharmacology and Therapeutics, March 2011, Dallas, TX.

Schoedel KA. Defining abuse potential in clinical studies: Practical approaches to a complex analytical problem. The Second International Symposium on Biopharmaceutical Statistics, March 2011, Berlin, Germany [FDA invited oral presentation].

Blanchard R, Sun H, McCrea J, Schoedel KA, Ngo P, Li X, Panebianco D, Rosen L, Murphy G, Sellers EM. A clinical study of abuse potential suggests that telcagepant exhibits no potential for recreational abuse. American Headache Society (AHS) 52nd Annual Scientific Meeting, June 2010, Los Angeles, CA.

McMorn S, Schoedel KA, Zerbe K, Chakraborty B, Potts SL, Sellers EM. Drug liking and cognitive/psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. 21st Annual Meeting and Symposium of the American Academy of Addiction Psychiatry, December 2010, Boca Raton, FL.

Sellers EM, McMorn S, Schoedel KA, Zerbe K, Chakraborty B, Potts SL. Comparison of drug liking and positive subjective effects of oral intact extended-release oxymorphone and controlled-release oxycodone. PAINWeek’10, September 2010, Las Vegas, NV.

Shram MJ, Schoedel KA, Turncliff R, Sellers EM. Test-retest reliability of pharmacodynamic measures used in abuse potential testing: Evidence from repeated administration of remifentanil, a short-acting potent opioid agonist. 13th World Congress on Pain, August 2010 Montréal, QC.

Schoedel KA, Saubadu S, Delfolie A, Pinquier JL, Sellers EM. Eplivanserin has no significant abuse potential compared to diazepam and ketamine in recreational drug users. 23rd European College of Neuropsychopharmacology Congress, August 2010, Amsterdam, Netherlands.

Schoedel K, Chen N, Guy GW, Wright S, Patel A, Whitel L, Stott CG, Russo E, Sellers E. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. 23rd European College of Neuropsychopharmacology Congress, August 2010, Amsterdam, Netherlands.

Levy-Cooperman N, Schoedel KA, Chen N, Feltner D, Billing Jr. CB, Sellers EM. Assessing potential for drug abuse in humans: Defining clinical important differences in subjective pharmacodynamic measures. Basic & Clin Pharmacol & Toxicol 2010; 107 (Suppl. 1): 409.

Turncliff R, Illeperuma A, Shram M, Forma R, Silverman B, Ehrich E, Sellers EM. A novel opioid receptor antagonist, ALKS 33, demonstrates full and durable blockade of remifentanyl. College on Problems of Drug Dependence, Abstracts of 72nd Annual Meeting, 2010: 171, Scottsdale, AZ.

Schoedel K, Chen N, Levy-Cooperman N, Feltner D, Sellers EM. Relative performance of subjective measures used in human abuse potential studies. College on Problems of Drug Dependence, Abstracts of 72nd Annual Meeting, 2010: 146, Scottsdale, Arizona.

Sellers EM, McMorn S, Schoedel KA, Zerbe K, Chakraborty B, Potts SL. Oral intact extended-release oxymorphone is associated with less euphoria and lower positive subjective effects than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users. 29th Annual Scientific Meeting of the American Pain Society, 2010, Baltimore, MD.

Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Abuse potential assessment of lorcaserin, a selective and potent agonist at the serotonin 2C (5-HT2C) receptor, in healthy male and female recreational polydrug users. Clin Pharmacol Ther 2010; 87(Suppl 1): S10.

Shram MJ, Schoedel KA, Bartlett CA, Shazer RL, Anderson CM, Sellers EM. Abuse potential evaluation of lorcaserin, a selective and potent agonist at the serotonin 2C (5-HT2C) receptor, in healthy male and female recreational polydrug users. 48th Annual Meeting American College of Neuropsychopharmacology, 2009, Hollywood, FL.

Sellers EM, Meier D, Chakraborty B, Manniche PM, Schoedel K. Tesofensine has no or minimal abuse potential in recreational drug Users: A randomized, double-blind, crossover study. Obesity 2009; 17(Suppl. 2): S114.

Schoedel K, Meir D, Chakraborty B, Manniche P, Sellers E. Tesofensine, a novel weight management drug, has no or minimal abuse potential. 17th European Congress on Obesity, 2009, Amsterdam, Netherlands.

Schoedel KA, Chen N, Sellers E. Abuse potential of nabiximols oromucosal spray in recreational marijuana users. College on Problems of Drug Dependence, Abstracts of 71st Annual Meeting June 25-29, 2009, Reno/Sparks, NV.

Milovan D, Schoedel KA, Romach MK, Sellers EM. Effect size, time and dose response profiles of drugs of abuse in human abuse potential studies. College on Problems of Drug Dependence, Abstracts of 71st Annual Meeting, 2009:103, Reno/Sparks, NV.

Sellers EM, Meier D, Chakraborty B, Manniche P, Schoedel KA. Lack of abuse potential of tesofensine in recreational stimulant users. College on Problems of Drug Dependence, Abstracts of 71st Annual Meeting, 2009: 138, Reno/Sparks, NV.

Schoedel KA. Selecting the best measures of abuse liability in human abuse liability studies. College on Problems of Drug Dependence, June 25-29, 2009, Reno/Sparks, NV.

Schoedel KA, Chakraborty B, Addy C, Rosko K, Maes A, Chen N, Sellers EM. Abuse potential of taranabant, a cannabinoid 1 receptor (CB1R) inverse agonist: a randomized, double-blind, crossover study in recreational polydrug users. College on Problems of Drug Dependence, Abstracts of 71st Annual Meeting, 2009: 136, Reno/Sparks, NV.

Shram MJ, Thipphawong J, Romach M, Sellers EM. Assessing the abuse potential of an oral osmotic-controlled extended release (OROS) hydromorphone compared to immediate release hydromorphone. J Pain 2009: 10(4, Suppl. 1): S45.

Andersen C, Høyrup Hemmingsen P, Lindhardt K, Schoedel K, Sellers E. Recreational drug user preferences: Egalet® opioids have low abuse and tampering attractiveness relative to marketed opioids. J Pain 2009; 10(4, Suppl. 1): S60.

Schoedel KA, Rosen LB, Alexander R, Wang J, Snavely D, Murphy MG, Chodakewitz J, Mengel H, Romach MK, Sellers EM. A single-dose randomized, double-blind, crossover abuse liability study to evaluate the subjective and effects of gaboxadol and zolpidem in recreational drug users. Clin Pharmacol Ther 2009; 85(Suppl. 1): S22.

Sellers EM, Shram, MJ, Thipphawong J, Romach MK. Human abuse liability of oral osmotic-controlled extended release hydromorphone vs. immediate release hydromorphone. Clin Pharmacol Ther 2009; 85(Suppl. 1): S22.

Romach MK, Schoedel KA, Rosen LB, Alexander R, Wang J, Snavely D, Murphy MG, Chodakewitz J, Sellers EM. Adverse effects of gaboxadol and zolpidem at high doses in recreational drug users. 47th Annual Meeting of the American College of Neuropsychopharmacology, 2008, Scottsdale, AZ.

Sellers EM, Shram MJ, Thipphawong J, Romach MK. Human abuse liability of oral osmotic-controlled extended release hydromorphone vs. immediate release hydromorphone. 47th Annual Meeting of the American College of Neuropsychopharmacology, 2008, Scottsdale, AZ.

Schoedel KA, Romach MK, Sellers EM. Human abuse potential studies: Subjective response patterns and clinically relevant effects of abuse drugs. Eur Neuropsychopharmacolg 2008; 18(Suppl. 4): S537.

Shram MJ, Sellers EM. Abuse liability evaluation during CNS drug development. 2nd Annual Pain Therapeutics Summit, 2008 [oral presentation].

Shram MJ, Thipphawong J, Romach M, Sellers EM. Abuse potential assessment of an oral osmotic-controlled extended release hydromorphone vs. immediate release hydromorphone. IX World Conference on Clinical Pharmacology and Therapeutics, 2008, Quebec City, PQ.

Sellers EM, Shram MJ, Romach MK, Thipphawong J. Test-retest reliability of pharmacodynamic measures used in abuse potential studies: Evidence from an immediate release formulation of hydromorphone. IX World Conference on Clinical Pharmacology and Therapeutics, 2008, Quebec City, PQ.

Miguelez M, Schoedel K, Romach MK. Abuse liability evaluation of cannabinoids in clinical studies. 17th Annual Symposium of the International Cannabinoid Research Society, June 27 – July 1, 2007, St. Sauveur, PQ.

Sellers EM., Setnik B, Schoedel KA. Collecting abuse liability data during CNS drug development. Drug Information Association Annual Meeting, June 17-21, 2007, Atlanta, GA.

Parasrampuria DA, Schoedel KA, Schuller R, Cicone P, Silber S, Sellers EM. A double-blind, placebo-controlled, randomized, crossover study to assess the pharmacokinetics and pharmacodynamics of abuse potential for OROS® methylphenidate versus immediate-release methylphenidate. American Psychiatric Association Annual Meeting, January 4-7, 2007, San Diego, CA.

Grigorova M, Schoedel K, Boris B, Thomas D, Sellers EM. Next-day measures may not be reliable for the assessment of subjective effects of alprazolam in recreational users. College on Problems of Drug Dependence, Abstracts of 69th Annual Meeting, 2007:70, Quebec City, PQ.

Shram MJ, Funk D, Li Z, Lê AD. Response cost influences nicotine self-administration differentially in adolescent and adult rats. 13th Annual Meeting of the Society for Research on Nicotine and Tobacco, 2007.

McColl SL, Schoedel K, Danilov B, Romach MK, Sellers EM. Improving signal detection in human abuse liability studies: A case for using prestudy pharmacological testing. College on Problems of Drug Dependence, Abstracts of the 68th Annual Meeting, 2006:130, Scottsdale, AZ.

Sellers EM, Schoedel KA, Schuller R, Romach MK, Horbay GLA. A structured field study assessing the abuse potential of different opioid formulations in Canada. College on Problems of Drug Dependence, Abstracts of 68th Annual Meeting, 2006: 178, Scottsdale, AZ.

Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Cicone P, Silber S, Sellers EM. Abuse potential of OROS® methylphenidate versus immediate-release methylphenidate and placebo. American Academy of Child and Adolescent Psychiatry, October 24-29, 2006, San Diego, CA.

Schoedel KA, Parasrampuria DA, Schuller R, Silber SA, Sellers EM, Pharmacodynamic (PD) modeling of subjective effects in a randomized double blind crossover abuse liability study of OROS® (Oros-MP) and immediate release methylphenidate (IR-MP) in recreational stimulant users. Clin Pharmacol Ther 2006; 79(2): 57.

Shram MJ, Li Z, Funk D, Lê AD. Age differences in the motivational properties of nicotine and mecamylamine-precipitated withdrawal. 12th Annual Meeting of the Society for Research on Nicotine and Tobacco, 2006.

Parasrampuria DA, Schoedel KA, Schuller R, Mulberg AE, Gu J, Silber S, Sellers EM. Abuse Potential of OROS Methylphenidate Versus Immediate-Release Methylphenidate and Placebo. American Academy of Child and Adolescent Psychiatry, October 18-23, 2005, Toronto, ON.

Shram MJ, Funk D, Lê AE (2005). Behavioural vulnerability to nicotine and alcohol in adolescent rats. 15th Annual Meeting of Brain, Behaviour, and Cognitive Sciences, 2005 [oral presentation].

Shram MJ, Chau V, Funk D, Lê AE. Age differences in the aversive properties of alcohol. 28th Annual Meeting of the Research Society on Alcoholism, 2005.

Clinical Pharmacology, Neuropharmacology and CNS Drug Development

Hopyan T, Danilov B, Schoedel KA. The neurocognitive effects of drug-induced changes for Choice Reaction Time in recreational polydrug users. CNS Diseases World Summit, September 22-23, 2011, San Francisco, CA.

Harrison SJ, Levy-Cooperman N, Danilov B, Schoedel KA. Drug-induced changes in performance on the Divided Attention Task in subjects with a history of recreational drug use. European College of Neuropsychopharmacology, September 3-7, 2011, Paris, France.

Levy-Cooperman N, Setnik S, Chen N, Chakraborty B, Schoedel KA, Romach M, Sellers EM, Sommerville K, Goli V. Pharmacokinetic interaction and safety of naltrexone hydrochloride co-administered with oral opioids. International Narcotics Research Conference, June 21-25, 2011, Hollywood, FL.

Levy-Cooperman N, Hammerness P, Surman C, Meller B, Reches A, Pinchuk N, Ben Bashat G, Shani-Hershkovitch R, Geva AB, Kerem D, Romach MK, Biederman J, Sellers EM. Characterizing drug effects on brain network activation: A novel analysis of EEG evoked response potentials. American College of Neuropsychopharmacology, December 4-8, 2010, Miami, FL.

Quinn AM, Shram MJ, Faulknor J, Sellers EM, Luong D. Differences between in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada. 8th Annual Canadian Meeting of the Drug Information Association, 2010.

McMorn S, Schoedel KA, Zerbe K, Chakraborty B, Potts SL, Sellers EM. Oxymorphone ER vs oxycodone CR: Psychomotor/cognitive impact. American Academy of Pain Management, September 2010, Las Vegas, Nevada.

McMorn SO, Schoedel KA, Chakraborty B, Sellers EM. Oral intact extended-release oxymorphone has fewer subjective and cognitive effects than equianalgesic controlled-release oxycodone. College on Problems of Drug Dependence, Abstracts of 72nd Annual Meeting, 2010: 110, Scottsdale, AZ.

Levy-Cooperman N, Reches A, Milovan D, Pinchuk N, Ben Bashat G, Shani-Hershkovitch R, Geva AB, Deouell LY, Romach MK, Sellers EM. Assessment of neurophysiological spatiotemporal networks and neurocognitive performance in healthy volunteers following administration of scopolamine and ketamine in a double-blinded, placebo-controlled, crossover study. European College of Neuropsychopharmacology, August 28-September 01, 2010, Amsterdam, Netherlands.

Milovan D, Levy-Cooperman N, Sellers EM, Reches A, Pinchuk N, Ben Bashat G, Shani-Hershkovitch R, Deoull LY, Geva AB. Assessment of scopolamine induced cognitive deficits using a novel algorithm for brain network activity (BNA) analysis: Application to schizophrenia. 14th Annual Meeting of the Israel Society for Biological Psychiatry, 2010. Kibutz Hagoshrim, Israel.

Pope LE, Kaye R, Hepner A, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between dextromethorphan/quinidine and memantine. 163rd Meeting of the American Psychiatric Association, 2010, New Orleans, LA.

Sellers EM, Schoedel KA, McMorn S, Zerbe K, Chakraborty B, Potts SL. Oral intact extended-release oxymorphone is associated with less cognitive and psychomotor impairment than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users. 29th Annual Scientific Meeting of the American Pain Society, 2010, Baltimore, MD.

Levy-Cooperman N, Danilov B, Romach MK, Sellers EM. Drug-induced changes in performance on the Divided Attention Task in subjects with a history of recreational drug use. 62nd Annual Meeting of the American Academy of Neurology, 2010, Toronto, ON.

Levy N, Ramirez J, Scott CJM, Lobaugh N, Caldwell C, Black SE. Progression of white matter hyperintensities in Alzheimer’s Disease. 3rd Congress of the International Society for Vascular Behavioural and Cognitive Disorders, July 2007, San Antonio, TX.

Levy N, Gao F, Black S. The relationship of subcortical MRI hyperintensities and medial temporal lobe atrophy. 16th Annual Rotman Research Institute Conference, March, 2006, Toronto, ON.

Levy N, Nadkarni, N, Black SE. Executive function and cerebral perfusion in Alzheimer’s Disease and Frontotemporal Dementia. 34th Annual Meeting of the International Neuropsychological Society, February, 2006, Boston, MA.

Levy N, Burhan A, Black S. Brain correlates Of depressive symptoms in Alzheimer’s Disease (AD): A SPECT study focusing on frontal-limbic circuitry platform. 57th Annual Meeting of the American Academy of Neurology, April 2005, Miami Beach, FL.

Levy N, Ramirez J, Lobaugh N, Caldwell C, Black SE. Subcortical hyperintensities and frontal lobe function: a quantitative SPECT and MRI correlation study. 2nd Congress of the International Society for Vascular Behavioural and Cognitive Disorders, June, 2005, Florence, Italy.

Levy N, Lobaugh N, Caldwell C, Gao F, Black S. Impact Of cerebrovascular comorbidity on prefrontal SPECT perfusion imaging in Alzheimer S Disease. 52nd Annual Society of Nuclear Medicine Meeting, June, 2005.

Levy N, Rafi-tari S, Caldwell C, Black SE. Impact of subcortical hyperintensities on SPECT regional cerebral perfusion in Alzheimer’s Disease. 11th Annual Organization for Human Brain Mapping Meeting, June 2005, Toronto, ON.

Mandzia JL, Gao FQ, Ramirez J, Levy N, Caldwell C, Black SE. Multimodal, in vivo functional and structural neuroimaging biomarkers in amnestic MCI. 11th Annual Organization for Human Brain Mapping meeting, June, 2005, Toronto, ON.

Levy N, Caldwell C, Lobaugh N, Black SE. Impact of subcortical ischemic changes on frontal SPECT perfusion in Alzheimer’s Disease. 27th National Conference of the Alzheimer’s Society of Canada, April 2005, Regina, SK.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download